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ABSTRACT 
 Clostridioides difficile infections (CDI) are bacterial infections severely affecting 
an individual’s health and financially affecting health care settings. These infections are a 
persistent health care issue despite implementation of preventative measures. Research on 
the risk of acquiring CDI for individuals with comorbidities is scarce. Diabetes mellitus 
(DM) may negatively impact an individual’s immune system and consequently increase 
the risk of CDI. The purpose of this pilot study was to determine if the incidence of DM 
differed between patients who had CDI and patients who did not have CDI. After 
receiving an Internal Review Board (IRB) exempt status, electronic medical records were 
reviewed from patients who were discharged from one healthcare facility in Maine to 
analyze the potential link between CDI and DM using a case-control study design. Cases 
(n=40) were included if they were diagnosed with positive CDI and had admission dates 
between 12/2016-12/2018. Controls (n=40) did not have a diagnosis for CDI and had 
admission dates between 12/2016-12/2018. Exclusion criteria for cases and controls 
included oncological patients and patients under 18 years of age. The data was analyzed 
using a Pearson chi square test. The p value was set at <.05. The p value calculated from 
the data was 0.485. The findings were not statistically significant. In terms of this study, 
there is no relationship between CDI and DM. Limitations included the lack of diversity 
in data collection and the fact that only one health care facility was utilized. In addition, 
potentially important factors like demographics and other underlying comorbidities were 
not considered in this analysis. Further exploration is needed on understanding the 
relationship between comorbidities and CDI, which has the potential to impact prevention 
 
   
methods thus leading healthcare facilities to possibly see a decrease in CDI rates and 
healthcare costs, and an increase in patient safety.  
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CHAPTER I: BACKGROUND 
Introduction 
Clostridioides difficile, formerly known as Clostridium difficile and referred to as 
C. difficile and C. diff, is an anaerobic gram-positive bacterium is one of the main causes 
of healthcare associated infectious diarrhea (Center of Disease Control [CDC], 2017). 
Clostridioides difficile infections (CDI) create a persistent challenge in health-care 
facilities around the globe. In 2019, there were 223,900 cases of CDI in hospitalized 
patients in the United States (U.S.) (CDC, 2019a). The CDC labels CDI as “an urgent 
threat,” costing the U.S. 15,000 deaths annually in acute care facilities alone and $4.8 
billion annually in excess health care costs (CDC, 2017). In addition, one in five patients 
with hospital-associated CDI suffers from recurrence while one in eleven patients aged 
65 and older die within 30 days of CDI diagnosis (CDC, 2017). While CDI is typically 
described as a nosocomial infection originating in a hospital, it can also appear in the 
community. An estimated 15,000 to 180,000 additional cases occur annually in 
community-dwelling persons (Juneau et al., 2013). The prevalence, cost, and danger of 
CDI highlights the need to focus on gaining more knowledge about this disease that can 
lead healthcare organizations towards additional methods of prevention. Comorbidities 
affecting an individual’s susceptibility to CDI is an area of research that is lacking. The 
focus of this study is to explore the potential relationship that one comorbidity, diabetes 
mellitus, and CDI have.  
The Pathology, What Happens? 
C. difficile lives naturally in the human gut microbiota as well as in the 
environment in places such as soil, water, and other animals (Seekatz & Young, 2014). 
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The bacterium can exist in the feces of someone with CDI as spores, which are 
metabolically inactive structures produced by the bacterium when the environment is less 
than favorable. These dormant spores can live on surfaces and in the soil for months or 
sometimes years due to their protective proteinaceous coats, which makes the prevention 
of the transmission of spores difficult (Paredes-Sabja et al., 2015). Infection can occur 
from ingestion of the bacteria themselves or the extraneous spores. C. difficile spores 
remain dormant until exposed to bile salts within the gastrointestinal tract. Bile salts 
trigger the spores to germinate, resulting in vegetative cells (Edwards et al., 2016). These 
cells then colonize in the gastrointestinal tract (Seekatz & Young, 2014). When 
colonization occurs, there is multiplication and growth of the organism on or within the 
host. With colonization, the patient is likely asymptomatic (Dani, 2014). 
Colonization of C. difficile is generally resisted through gut microbiota and host 
immune response (Harris et al., 2018). When gut microbiota is undisturbed, it provides 
effective resistance against C. difficile infection. In fact, normal gut microbiota is made-
up of about 100 trillion bacterial cells and up to 2,000 different kinds of bacteria 
(Guinane & Cotter, 2013). Microbiota are critical to gut function aiding in many specific 
functions including nutrient metabolism, drug metabolism, maintenance of structural 
integrity of the gut mucosal barrier, immodulation, and protection against pathogens 
(Jandhyala, 2015). According to Jandhyala (2015), in a healthy individual, these bacteria 
keep C. difficile bacteria controlled. However, when there is a disturbance in normal gut 
microbiota, C. difficile is given the opportunity to colonize to pathogenic levels. For 
example, when antibiotics are used long-term, the normal flora (i.e., microbiota) of the 
gut is suppressed. Broad spectrum antibiotics are non-selective, meaning they kill the 
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infectious bacteria and the bacteria that are normally in your gut, thereby decreasing the 
colonization of beneficial bacteria. Another reason that C. difficile can live in the human 
colon is the anoxic environment, meaning there is a depletion of oxygen. Because C. 
difficile is an anaerobic organism, this makes it the perfect environment to survive, and 
even proliferate (Abt et al., 2016).  
Once proliferated, C. difficile produces two exotoxins that cause disease: TcdA 
and TcdB. These two toxins result in infection and symptoms. TcdA is an enterotoxin 
that activates macrophages and mast cells. Mast cells release inflammatory mediators, 
which then disrupt the cell wall junction within the intestinal wall, resulting in increased 
permeability and diarrhea. TcdB is a cytotoxin that degrades the epithelial cells in the 
colon. TcdA and TcdB cause inflammation and cell death, which results in fluid 
accumulation and damage to the large intestine (Carter et al., 2010). This fluid 
accumulation can cause C. difficile symptoms and life-threatening sequelae.  
These two toxins are the primary markers for diagnosis of C. difficile and can be 
found through antibody-based and cytotoxicity assays of stools of patients (Voth & 
Ballard, 2005). There are many strains of C. difficile and they are largely divided and 
based on variations of these two toxins.  
Implications of Untreated Cases 
 C. difficile infection symptoms vary. Mild to moderate symptoms can include 
diarrhea, fever, stomach tenderness or pain, loss of appetite, or nausea (CDC, 2020a). 
More severe symptoms can include inflammatory lesions, the formation of 
pseudomembranes in the colon, the development of paralytic ileus (i.e., peristalsis has 
stopped), fulminant colitis, and toxic megacolon with toxigenic strains can be life-
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threatening (Hookman & Barkin, 2009). Fulminant colitis can include bowel perforation, 
sepsis, and shock (Hookman & Barkin, 2009). Toxic megacolon is a rare complication of 
inflammation in the colon and is the dilation of the colon more than 5 cm (Hoffman, 
2017).  
Early complications of C. difficile can be detected through imaging tests such as 
an abdominal x-ray or a computerized tomography (CT) scan. Through these images, 
complications such as the thickening of the colon wall, expansion of the bowel, or 
perforation of the colon can be detected (Mayoclinic, 2020; Sayedy & Richards, 2010). 
These diagnostic tests help to inform clinicians of the infection severity.    
 According to Hoffman and Sullivan (2017), severe diarrhea from C. difficile 
infection can lead to loss of significant amounts of fluids and electrolytes. This can cause 
insufficient vascular volume and decreased blood pressure, which can become 
dangerously low. With a loss of fluids from diarrhea, the patient has the potential to 
develop hypovolemic shock. This shock scenario from the lack of circulating volume 
causes a ripple effect in the body. With hypovolemic shock, tissue perfusion or blood 
flow to vital organs is jeopardized. This can cause problems, especially if the tissues are 
not receiving the necessary oxygen carrying blood to provide the tissues with the oxygen 
and nutrients that are critical for cellular metabolic function. One of the first organs to 
reflect inadequate tissue perfusion are the kidneys. This is because blood flow is 
redirected from nonessential organs (e.g., kidneys and gastrointestinal tract) to more vital 
organs such as the brain and the heart (Hoffman, 2017). The patient may exhibit oliguria 
or producing abnormally small amounts of urine (Hinds & Watson, 1999). If dehydration 
occurs quickly, kidney function can rapidly deteriorate (CDC, 2020b). If a C. difficile 
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infection is not treated promptly, multiple organs can be affected which may result in 
death. 
Risk Factors 
Known risk factors for developing CDI include antibiotic use, age, extended stays 
in healthcare settings, having a weakened immune system, and having a previous 
diagnosis of CDI (CDC, 2018). However, there are other risks for CDI that are being 
explored that include pharmacological factors, host-related factors, and clinical 
intervention factors. The use of a proton pump inhibitor (PPI), histamine 2 receptor 
antagonist, anti-ulcer medications, non-steroidal anti-inflammatory drug (NSAID), 
aspirin, and corticosteroids are all thought to be risk factors for CDI (Eze et al., 2017). 
Other factors within the host include being over the age of 65 or having any of the 
following diagnoses: chronic kidney disease (CKD), diabetes mellitus, lymphoma or 
leukemia, solid cancer or malignancy, inflammatory bowel disease (IBD), congestive 
heart failure (CHF), chronic obstructive pulmonary disease (COPD), peptic ulcer, 
diverticular disease, gastroesophageal reflux disease (GERD), and being of the female 
sex (Eze et al., 2017). Clinical intervention risk factors include duration of 
hospitalization, the use of nasogastric tube feeding, staying in an intensive treatment unit, 
and a non-surgical GI procedure (Eze et al., 2017).  
Treatment 
Treatment for CDI can include medical and surgical approaches. With inpatients 
who have confirmed CDI and are on antibiotics, the treatment may include stopping the 
antibiotic (CDC, 2020a). In 20% of these cases, the CDI will resolve in two or three days 
of discontinuing the antibiotic treatment (CDC, 2020a). During treatment, laxatives are 
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also discontinued to rule out other explanations of diarrheal symptoms. In other cases, 
CDI is generally treated using the oral antibiotics vancomycin or fidaxomicin for 10 days 
(CDC, 2020a). Once the patient’s symptoms have resolved, repeat testing is not 
recommended, as the patient is likely to still be colonized with C. difficile (CDC, 2020a).  
Alternative treatments to CDI include fecal microbiota transplant (FMT) and the 
use of probiotics (Kim & Gluck, 2019). According to Kim and Gluck (2019), FMT is a 
new strategy and is still considered experimental. FMT is a procedure designed to restore 
the healthy microbiome in an affected individual. This is achieved through the delivery of 
stool from a healthy donor to an individual who has an illness, such as CDI, that is 
believed to be related to an unhealthy gut microbiome. Modalities of administration 
include direct translocation into the colon or into the upper gastrointestinal tract through 
the ingestion of a capsule, or through a nasoenteric tube (Kim & Gluck, 2019). Clinical 
studies have shown that FMT, when done one or more times, can have success rates 
higher than 85% (United States Food and Drug Administration, 2019). Despite the 
success rates of FMT, barriers remain including the long-term effects, adequate 
monitoring of recipient fecal matter, maintaining reasonable costs, and determining the 
characteristics of a healthy microbiome (Kim & Gluck, 2019). 
Probiotics are also considered to be an experimental intervention and can include 
bacteria and yeast. However, these treatments have not been shown to consistently 
prevent or treat a patient with CDI (Na & Kelly, 2017). Clinical studies surrounding more 
advanced probiotics are currently being studied in clinical trials to explore their potential 
in preventing or treating CDI (Na & Kelly, 2017).  
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Isolation Techniques (Prevention) 
 C. difficile can be transmitted horizontally via the fecal-oral route (Enoch & 
Aliyu, 2012). Although CDI is widely spread outside of healthcare facilities, deliberate 
actions towards CDI prevention should be practiced inside and outside of healthcare 
facilities (Gould et al., 2019). Proper hand hygiene and regular cleaning with bleach can 
help reduce the spread of CDI (Barbut & Petit, 2001;CDC, 2020a).  
Current methods to prevent the transmission of spores and the bacterium itself 
include hand washing with soap and water, the use of PPE, and the use of chlorine bleach 
to wash inanimate objects (Paredes-Sabja et al., 2014). Despite the implementation of 
these preventative measures, CDI infections continue to be a pressing issue. Infection 
control protocols are implemented to help expedite evaluation and isolation of patients 
who are suspected to have CDI. Dedicated, patient-specific equipment such as blood 
pressure cuffs and stethoscopes are provided to the affected patient to help reduce the 
spread, and are left in the patient’s room for the duration of their hospital stay to 
minimize risk of transmission to others (CDC, 2020a). 
There are a number of laboratory tests that can be done to determine if someone 
has a CDI. These tests are used to determine the presence of toxins produced by C. 
difficile. Examples of such laboratory tests include polymerase chain reaction (PCR), 
glutamate dehydrogenase (GDH) in conjunction with enzyme immunoassay (EIA) test, 
enzyme immunoassay, and cell cytotoxicity assay (CDC, 2020a). If CDI is suspected, the 
patient should be isolated immediately, and contact precautions should be enacted. 
Contact precautions require the use of personal protective equipment (PPE) and include 
wearing gowns and gloves upon entry of the room and discarding when leaving the room. 
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This should be followed with rigorous hand washing (20 seconds) with soap and water. 
Hand washing is the gold standard for effective prevention measures because hand 
washing physically removes spores from the hands. Alcohol-based hand rubs are not 
considered reliably sporicidal (CDC, 2020a).  
If the patient tests positive for CDI, then isolation and contact precautions should 
be continued (CDC, 2020b). Their room should be cleaned thoroughly with bleach or 
another EPA-approved spore-killing disinfectant daily and upon discharge (CDC, 2020b). 
Providers should use antibiotics only when necessary to avoid the risk of CDI (CDC, 
2020b). Education should be provided to all persons who come in contact with the 
positive individual, stressing the importance of complying with contact precautions and 
hand washing with soap and water (CDC, 2020b).    
The Cost of CDI 
Diagnosis of CDI has far reaching implications on a number of levels. For the 
individual, CDI can mean significant damage to vital body organs as well as the 
possibility of death. Although CDI can be treated using oral and/or intravenous 
antibiotics, recurrence of CDI is common, affecting 15-35% of patients who have had 
successful treatment of the initial episode (El-Matary et al., 2019). Most of the time, CDI 
is a relapse of the initial infection, and not a re-infection of a new strain because of the 
altered colonic microbiota (El-Matary et al., 2019). In other words, the original C. 
difficile bacteria are still present in the gut, despite treatment. The patient may not be 
showing symptoms because other bacteria within the gut keep C. difficile to non-
pathogenic levels. Once recurrence has occurred, subsequent recurrences are more 
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common. Risk factors for recurrent CDI include being over the age of 65 and antibiotic 
use (El-Matary et al., 2019).   
The development of treatment guidelines to prevent the recurrence of CDI are 
ongoing (El-Matary et al., 2019). The development of more virulent strains and increased 
incidence has led to chronic, recurrent CDI cases. Such strains include hypervirulent 
strains BI/NAP/027 (Cole & Stahl, 2015). These strains are notorious for producing 
greater amounts of toxins A and B. They also show fluoroquinolone resistance, making 
the treatment of reinfections of CDI difficult. Fluoroquinolone is a broad-spectrum 
antibiotic commonly used to treat CDI.  
In terms of the U.S. healthcare system, CDI poses a significant financial burden. 
One study conducted by Zhang et al. (2016) found that the average cost for CDI case 
management and average CDI-attributed costs per case was $42,316.00. To date, C. 
difficile is the number one microbial healthcare-associated infection (HAI) in U.S. 
hospitals (CDC, 2019a). In the state of Maine, CDIs are mandated as reportable 
infections for acute care facilities. Hospitals must report CDIs to the Maine CDC in order 
for participation in the Centers for Medicare and Medicaid Services (CMS) Hospital 
Inpatient Quality Reporting Program (CDC, 2019a). The incentive for participation in 
such a program is known as “pay for reporting” where hospitals that participate and meet 
all requirements as outlined by CMS are paid more than hospitals that do not participate. 
Acute care hospitals that are paid for treating Medicare beneficiaries have the ability to 
receive the full Medicare annual payment, granted that certain quality data is reported in 
the form, manner, and time as requested by CMS (CMS, 2020).  
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The CMS utilizes a risk adjustment model as a way to offset the cost of providing 
health insurance to individuals who are considered high risk, such as those with chronic 
health conditions (American Academy of Professional Coders [AAPC], 2020). Under the 
Affordable Care Act, insurers who cover greater than average healthy individuals must 
pay into a ‘risk adjustment pool’. These funds are then allocated to insurers who enroll 
greater than average high-risk individuals to make up for extra costs. With the risk 
adjustment model, several variables are taken into account to determine a risk score, 
which can be extrapolated to predict the probable costs to insure the individual (AAPC, 
2020). CMS uses the Hierarchical Condition Category (HCC) which ranks diagnoses into 
categories that represent conditions that are similar in cost. Diagnoses are identified by 
International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-
CM) which is a tool utilized by the CDC that codes and classifies mortality data from 
death certificates (CMS, 2020). It consists of more than 68,000 codes and has the ability 
to reveal more about the quality of care and enable better tracking of public health and 
risks. It is important to note that not all diagnoses in the International Classification of 
Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) will ‘risk adjust’ (CDC, 
2015).  
Currently, for hospital-onset CDI, the CDC National Healthcare Safety Network 
(NHSN) risk adjusts for the following: academic or nonacademic affiliation, number of 
beds, type of C. difficile testing, community-onset prevalence, and number of ICU beds 
(Harris et al., 2018). Based on this information, CMS will determine the projected 
prevalence rate for a facility. Once that prediction is made, hospitals are to not exceed 
this rate. If a hospital has more than the projected number of cases and spends more 
 
  11 
money than the predicted cost, the hospital still receives the set Medicare annual payment 
and nothing more. In other words, the hospital will assume the cost of anything over what 
CMS predicts they will spend (Harris et al., 2018). However, none of the variables 
adjusted for are patient-level, meaning they are generalized to the hospital and not 
specific to the patient.  
Diagnoses are not taken into account for CDI. For instance, if a patient has a 
potential risk factor, the risk factor will not be taken into account when charging the 
institution for the patient’s care. According to Harris et al. (2018), CMS does not take 
comorbidities (e.g., heart disease or diabetes mellitus [DM]) into account when 
reimbursing hospitals. Therefore, the hospital where a CDI infection is contracted 
assumes financial responsibility with all patients even those with comorbidities that 
increase their risk for CDI; the hospital may have to pay for that treatment out of pocket 
if that patient were to contract CDI.  
Pathology of DM 
Research regarding the link between CDI and diabetes mellitus (DM) is scarce. 
Diabetes mellitus is a chronic health condition that is centered around disturbances in 
blood glucose homeostasis. DM affects how the body is able to utilize glucose as an 
energy source. Glucose is a simple sugar that is one of the body’s preferred sources of 
fuel (Palicka, 2002). It is the primary source of energy for humans. Glucose is absorbed 
from the intestine and is metabolized by energy production (by conversion to water and 
carbon dioxide), conversion to amino acids and proteins or keto-acids, and storage as 
glycogen. When there is a rise in glucose in the bloodstream, the pancreas is signaled to 
release insulin (Palicka, 2002).  
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The pancreas is an exocrine and endocrine organ that plays a vital role in the 
regulation of blood sugar homeostasis (Hoffman, 2017). Using two hormones, glucagon 
and insulin, the pancreas is able to adapt to the increases and decreases in blood sugar 
levels (Roder et al., 2016). For example, blood sugar decreases during exercise and sleep. 
In response, alpha cells located within the pancreas release glucagon, which drives 
hepatic and renal gluconeogenesis in order to increase endogenous blood glucose levels 
(Roder et al., 2016). Alternatively, if there is a rise in blood sugar levels, such as during 
mealtimes, beta cells on the pancreas release insulin. Insulin then attaches to receptors 
found on muscle and adipose tissue, acting as a key, allowing the glucose molecule to 
enter these tissues (Hoffman, 2017; Roder et al., 2016). Without the presence of insulin, 
blood sugar cannot enter cells, thereby causing a buildup of glucose in the bloodstream 
(Hoffman, 2017). 
DM: Type I and Type II 
There are two main etiologies of DM: type I and type II. Type I is thought to be a 
result of an autoimmune reaction. As a result, there is a complete loss or minimal 
production of insulin. During this reaction, the beta cells located on the pancreas are 
destroyed (Hoffman, 2017). Approximately 5-10% of DM cases are type I, and it is often 
diagnosed in children, teens, and young adults. To date, there are no methods of 
prevention, and daily exogenous insulin (i.e., injection) is necessary in order to survive 
(CDC, 2019b).  
Type II DM occurs when the body does not respond normally to insulin, resulting 
in insulin resistance (CDC, 2019b). The pancreas recognizes this resistance and produces 
more insulin to try and compensate. Eventually, the pancreas cannot keep up with the 
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body’s increased blood sugar levels. Type II DM is much more common than type I. 
More than 34 million Americans have DM, and 90-95% of them have type II DM (CDC, 
2019b).  
Hyperglycemia and hypoglycemia are two complications that can occur with both 
type I and type II DM (Hoffman, 2017). Hyperglycemia occurs when blood glucose 
levels rise above what is normal, which is between 65-99 mg/dL (Hoffman, 2017). In an 
effort to decrease blood glucose levels, glucose is excreted in the urine. Typically, 
glucose is reabsorbed in the renal tubules. When glucose is excreted, water reabsorption 
by the renal tubules is also reduced, leading to large amounts of fluid being released in 
the urine. Increased urine output is known as polyuria, and is a symptom of DM 
(Hoffman, 2017). In addition, there is hyperosmolarity in the blood which pulls water 
from the cells and into the vasculature. In an attempt to counteract the large amounts of 
urine being passed and the water leaving the cells, the thirst mechanism is triggered, 
causing the individual to feel excessively thirsty. This is known as polydipsia, and is 
another feature of DM (Hoffman, 2017). 
Hypoglycemia is another complication that diabetics encounter (Hoffman, 2017). 
Hypoglycemia is defined as a blood glucose of less than 65 mg/dL (Hoffman, 2017). 
Hypoglycemia can occur for a number of reasons including a high dose of insulin 
administered, a high dose of oral medications that stimulate insulin release, a decrease in 
clearance of insulin from the body due to renal insufficiency, a decrease in nutritional 
intake, and increase metabolism of glucose through increased exercise. Alcohol 
consumption can also impact blood glucose levels by reducing the amount of glucose 
released from the liver (Hoffman, 2017). It can present as an acute event or a life-
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threatening emergency because of the potentially hazardous effects on the central nervous 
system. The central nervous system relies solely on glucose for its energy needs, unlike 
other tissues in the body (Hoffman, 2017). If there is not enough glucose, metabolic 
functioning cannot continue, and cell death may occur. When blood glucose levels drop, 
the body activates the sympathetic nervous system and releases the hormones 
epinephrine, norepinephrine, and glucagon (Hoffman, 2017). Symptoms of hypoglycemia 
include anxiety, sweating, hunger, shakiness, difficulty thinking, dizziness, fatigue, and 
slurred speech (Hoffman, 2017).  
Because of the lack of insulin, body cells are not receiving the preferred source of 
energy, glucose, needed to function. Pathologically, proteins and fats are broken down as 
sources of energy as a result (Hoffman, 2017). The cells are starving, which causes the 
patient to feel polyphagia, or an increased appetite. While the person may be eating large 
amounts of food, they will continue to lose weight and become fatigued, as their body is 
not able to utilize the glucose they are consuming (Hoffman, 2017). Hyperglycemia can 
lead to many serious health problems, including heart disease, vision loss, and kidney 
disease (CDC, 2020a).  
While there is no cure for DM, blood sugar levels can be managed using oral 
medications and exogenous insulin. According to the CDC (2020c) it is estimated that 
34.2 million adults in the U.S. that have DM, and one in five do not know they have 
developed this disease (CDC, 2020c). In the last 20 years, the number of adults diagnosed 
with DM has more than doubled (CDC, 2020c). It is the number one cause of kidney 
failure, lower-limb amputations, and acute blindness. It is also the seventh leading cause 
of death in the U.S. In 2016, a total of 7.8 million hospital discharges reported DM as a 
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listed diagnosis among US adults aged 18 years or older. In 2017, the total direct and 
indirect costs of diagnosed DM in the U.S. was $327 billion dollars (CDC, 2020c).  
The Immune Response: DM and Infection 
 When DM is uncontrolled or not well managed, hyperglycemia is a complication 
that can occur (Hoffman, 2017). Hyperglycemia that is associated with DM is thought to 
be linked to altered immune function. The immune system is the body’s defense against 
foreign invaders, such as viruses, fungi, and bacteria. Utilizing both chemical and 
physical barriers, it works to prevent infection and disease (Hoffman, 2017).  
The immune response is broken up into two distinct parts: innate (natural) and 
acquired (adaptive) (Hoffman, 2017). The innate immune system is the body’s first two 
lines of defense, and is nonspecific, meaning it is not tailored to a specific invader. The 
first line of defense is made up of physical, biochemical, and mechanical barriers 
(Hoffman, 2017). These three barriers work on the surface to prevent the invasion of 
microorganisms. First, the body must identify the invader as either self (self-antigen) or 
non-self (foreign-antigen). Once it has been identified as non-self, an attack is initiated in 
order to stop the invading microorganism (Hoffman, 2017).  
The second line of defense is also a nonspecific response, and is made up of the 
inflammatory response. This is comprised of interferons, complement, and phagocytosis 
(Hoffman, 2017). Phagocytosis refers to the ingestion of invading microorganisms by 
phagocytes. Factors that aid the inflammatory response include neutrophils, eosinophils, 
basophils, platelets, monocytes, lymphocytes, and mast cells (Hoffman, 2017). Proteins 
involved include complement, clotting factors, and kinins, in addition to cytokines and 
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chemokines (Hoffman, 2017). When the inflammatory response is activated, the goals are 
to attack the foreign invaders and to keep any tissue damage localized (Hoffman, 2017).  
Jafar et al. (2016) looked at the relationship between the innate immune system 
and acute hyperglycemia. Their focus was on cellular defenses, microcirculation, and the 
complement cascade.  Neutrophils are phagocytes and are a significant part of the innate 
immune system. These cells are the first to arrive to inflammatory sites, and work to 
attack the invading pathogens. Because neutrophils are crucial to eliminating pathogens, 
any damage or reduction in them takes a significant toll on the individual’s susceptibility 
to infection (Jafar et al., 2016). Another study conducted by Joshi et al. (2013) found that 
hyperglycemia decreases the ability to kill invading bacteria, due to the negative effect on 
neutrophil activity. Lastly, Mauriello et al. (2014) found that acute exposures to 
hyperglycemia significantly impacts the ability to fight infection against S. aureus, 
another bacterium, and chronic exposure to glucose causes chronic inflammation.  
Vasodilation, dilation of the vasculature, comes from increased capillary 
permeability and is necessary to increase blood flow and chemotaxis to the area of injury 
(Hoffman, 2017). Vasodilation results from histamine, kinins, prostaglandins, 
leukotrienes, and complement (Hoffman, 2017). Jafar et al. (2016) found that 
hyperglycemia affects the ability to vasodilate, especially during times of acute 
inflammation, hindering blood flow to the areas of infection. When vasodilation is 
affected, neutrophils’ response time to infection is reduced (Jafar et al., 2016). Lastly, the 
complement cascade is negatively affected in a hyperglycemic environment. The 
complement cascade is an early stage of the innate immune system (Jafar et al., 2016). It 
can cause direct lysis of invaders and control phagocytosis of microorganisms by 
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neutrophils. When this is negatively affected, an individual’s innate immune system is 
compromised.  
Damage to the vasculature can occur due to the damage that glucose molecules 
cause to the lining of the vasculature. This occurs due to a complex process that includes 
oxidative stress promoted by hyperglycemia, and the presence of free radicals (Paneni et 
al., 2013). Macrovascular damage can affect the large arteries that supply blood to the 
brain and the heart (Hoffman, 2017). Four out of five people with diabetes-related deaths 
die from cardiovascular disease. In addition, adults who have DM are 2-4x more likely to 
die from a myocardial infarction (MI), more commonly known as a heart attack, than 
those that do not have DM. A MI can occur when there is lack of blood and oxygen to the 
heart muscle, known as ischemia, resulting in tissue death, known as infarction 
(Hoffman, 2017). Likewise, the risk for stroke is 2-4x higher all people who have DM. 
Damage to the small vessels, or microvascular complications, can cause damage to the 
eyes, gums, kidneys, and can cause peripheral vascular disease (PVD). In addition, 
hyperglycemia can negatively affect nerve cells, resulting in diabetic peripheral 
neuropathy and autonomic neuropathy (Hoffman, 2017).  In sum, hyperglycemia, a 
common complication of DM has been shown to have a relationship with body system 
debilitation and can compromise the immune system which may predispose those 
afflicted to infectious processes such as CDI. Therefore, the purpose of this proposed 
study is to explore the potential link between CDI and DM: Are those with CDI more 
likely to have DM than those that do not have CDI? 
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Literature Review 
Risk Factors and CDI 
 CDI infections continue to pose a significant burden on the U.S. healthcare 
system despite implementation of preventative measures. Risk factors for CDI have been 
identified (increased hospitalization stay, increased age, antibiotic use, and previous CDI 
infection) and include the use of antibiotics and gastric acid suppression therapies (CDC, 
2020a). These risk factors are generally preventable as unnecessary use of these 
medications can be discontinued to decrease the risk of CDI (Harris et al., 2018). Other 
risk factors have been identified and explored. These include age, race, congestive heart 
failure (CHF), immune dysfunction, liver disease, kidney disease, and malignancy (Garey 
et al., 2008). While these factors are sometimes modifiable, it is important to analyze 
individual risk factors as they can shed light on other contributing factors to acquiring 
CDI. Further investigation on precipitating factors to CDI has the potential to decrease 
CDI incidence rates, as healthcare professionals will have a better understanding of why 
CDI occurred and can use that knowledge to help prevent future CDI in other individuals 
in similar circumstances. This literature review will discuss four risk factor themes: 
comorbidities and CDI, immunocompromised systems and CDI, hospitalization and CDI, 
and metformin and CDI.  
Comorbidities and CDI 
 Four studies examined comorbidities and CDI (Welfare et al., 2011; Lopeze-de-
Andres et al., 2018; Vondaran et al., 2018; Harris et al., 2019). These comorbidities 
include liver disease, organ transplant, weight loss, inflammatory bowel disease, recent 
bowel surgery, congestive heart failure, renal failure, coagulopathy, and malignant 
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tumors (Harris et al., 2019). Harris et al. (2019) determined that patients with comorbid 
conditions had a greater risk of hospital-onset CDI. Harris et al. (2019) was able to 
determine this through the use of the Elixhauser comorbidity index, which utilizes the 
ICD-10-CM codes. This tool adds 30 unweighted conditions to generate a score from 0-
30. The higher the score, the higher the risk that the patient has of contracting CDI. 
Harris et al. (2019) noted that this association remained strong even when they controlled 
for antibiotic therapy, age, and gastric acid suppression therapy.  
 Another tool used to measure the overall burden of comorbidities is the Charlson 
Comorbidity Index. This tool generates a number, which can be used to predict the ten-
year mortality of individuals who have various comorbidities (heart disease, AIDS, 
cancer, etc.). This number can be used to help predict clinical prognosis. For example, a 
physician may utilize this tool to predict the 10-year mortality of a patient newly 
diagnosed with cancer, who already has heart disease and AIDS. Depending on the score 
the patient is given, the physician can help the patient determine how aggressively they 
want to treat their cancer. Welfare et al. (2011) utilized this tool to determine the 
mortality rate of those with CDI, specifically, Clostridium difficile associated diarrhea 
(CDAD). They found that death at 30 days is predicted by age, presence of cancer, 
cognitive impairment, and cardiovascular, respiratory, and kidney comorbidities. These 
findings show that comorbidities can crucially impact mortality rate. By knowing which 
populations are more at risk for mortality related to CDI, more vigilant attention can be 
given to individuals with these comorbidities to help identify CDI in its early stages in an 
effort to start treatment measures more quickly. 
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  Fulminant CDI is a form of CDI that is severe and sudden in onset. Vondran et al. 
(2018) looked at fulminant CDI in patients after cardiac surgery. Their results showed 
that independent risk factors for fulminant CDI included preoperative DM type II, 
preoperative ventilation, and the utilization of more than 8 red blood cell units (Vondran 
et al., 2018). Vondran et al. (2018) discussed the impact of disturbance of the microbial 
intestinal flora and its relationship to CDI. In this cohort of patients, preventative 
screening and prophylactic therapies were unsuccessful. As a result, it was recommended 
that patients who are considered high risk for CDI be selected for close monitoring in 
order to provide intervention more quickly (Vondran et al., 2018).  
 Another study conducted by Lopeze-de-Andres et al. (2018) linked DM and CDI, 
stating that CDI rates were higher in patients with DM than those without. They point out 
that studies analyzing the impact of CDI on health outcomes in hospitalized patients with 
type II DM are scarce. The authors identified 44,695 hospitalizations of patients >40 
years old with CDI in Spain between 2001-2015. Of those, 21.19% had type II DM. 
Lopeze-de-Andres et al. (2018) found that patients with type II DM are 1.12 times more 
likely of being admitted to the hospital with CDI than patients with the same age and sex 
distribution but without DM. Moreover, the incidence for CDI was 1.26 times higher in 
patients with type II DM than those without DM.  Lastly, CDI as the primary diagnosis 
was significantly higher in patients with type II DM (35.19%) than in nondiabetic 
patients (33.62%) (Lopeze-de-Andres et al., 2018).  
 Through knowledge that identifies which comorbidities affect the acquisition or 
severity of CDI, proper preventative measures can be taken towards targeted individuals. 
For example, if a patient has a comorbidity that has a strong association with CDI, the 
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provider may be able to alter care (i.e., prescribe medications) to help reduce the risk of 
CDI. Since non-modifiable factors such as age (i.e. over 65) are considered at a higher 
risk for contracting CDI, there are fewer options for taking preventative measures. 
Therefore, it is important that modifiable risk factors be identified so that tailored 
preventative measures can be developed to reduce the risk of CDI among these 
populations.  
Immunocompromised and CDI 
 One risk factor for CDI is a compromised immune system (CDC, 2018), and 
patients with immunocompromised systems experience a higher incidence of CDI.  
Knowing that hyperglycemia, a complication of DM, has the potential to lead to an 
immunocompromised system, then DM as a comorbidity could impact the likelihood of 
developing CDI. Despite this logical link, the data linking CDI and DM is scarce. There 
were two articles discussing the relationship of DM and CDI (Shakov, 2011; Olanipekun, 
2016). One study conducted by Shakov et al. (2011) found a significant association 
between DM and CDI. Findings indicated that those that had DM were 8 times more 
likely to have recurrence of CDI than those without DM. Another study conducted by 
Olanipekun et al. (2016) found that CDI is independently associated with poorer health 
outcomes, higher in-hospital mortality, longer length of stay, and increased direct costs of 
inpatient care in patients with type II DM. Shakov et al. (2011) calculated the national 
prevalence of CDI among patients with type II DM was 6.8 per 1000 hospital discharges. 
Moreover, those that have type II DM and CDI have a 3-fold increase in mortality when 
compared to patients without CDI. These individuals also had a 50% to nearly 4 times 
higher length of stay and costs compared to those without CDI. Patients who were 
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receiving in-patient services and had a diagnosis of type II DM had a substantial increase 
in costs of $14,000 when having CDI (Shakov et al., 2011). It is important to note that 
these two studies presented a correlation between DM and CDI, not causation. In other 
words, their findings showed a link between DM and CDI. They did not find that DM 
causes CDI, or vice versa.  
Hospitalization and CDI 
 A risk factor for CDI includes extended stays in healthcare settings, particularly 
hospitals and nursing homes (CDC, 2018). There were three articles that discussed the 
relationship of hospitalization and CDI (Freedberg, 2017; Shaughnessy, 2011; Moss et 
al., 1999). Exposure to C. difficile in the hospital occurs frequently as the spores persist 
for months on surfaces such as the beds, bed rails, floors, and walls of the hospital rooms 
where prior patients have had CDI (Freedberg, 2017). Shaughnessy et al. (2011) found 
that patients were 3x more likely to acquire CDI when the prior room occupant had CDI. 
C. difficile can also be spread through carriers of the bacterium. Healthy individuals in 
the hospital can become colonized with C. difficile, meaning that the bacteria are residing 
in their gut microbiota, but no symptoms are present. Once colonized, C. difficile can be 
spread from person to person, making it essential to always practice hand hygiene even if 
you are asymptomatic (CDC, 2018). Because C. difficile can be spread through both 
human to human contact and through inanimate objects, the risk of acquiring C. difficile 
is increased when in healthcare settings. 
Those with DM are more likely to be hospitalized than those without DM (Moss 
et al., 1999). Inpatient care of those with DM may be required for life-threatening acute 
metabolic complications of DM (e.g., diabetic ketoacidosis, hyperglycemic hyperosmolar 
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state, and hypoglycemia with neuroglycopenia), newly diagnosed DM, substantial and 
chronic poor metabolic control, severe chronic complications of DM that require 
intensive treatment, uncontrolled or newly discovered insulin-requiring DM during 
pregnancy, and institution of insulin-pump therapy and other intensive insulin regimens. 
In addition, chronic cardiovascular, neurological, renal and other diabetics may evolve 
into a stage in which hospital admission is appropriate (American Diabetes Association, 
2004). In the CDC’s 2020 National Diabetes Statistics Report, it was reported that in 
2016 a total of 7.8 million hospital discharges had DM. This means that 339.0 per 1,000 
adults were discharged from hospitals with DM as a listed diagnosis in their medical 
record. Major reasons for these discharges included cardiovascular disease (75.3 per 
1,000 adults), lower-extremity amputation (5.6 per 1,000 adults), hyperglycemic crisis 
(9.1 per 1,000 adults), and hypoglycemia (2.5 per 1,000 adults; CDC, 2020). For certain 
procedures, such as lower-extremity amputations, antibiotics may be given 
prophylactically to prevent infection from occurring. Depending on the antibiotic given, 
normal flora has the potential to be disturbed. The use of antibiotics and increased 
hospital stay are both risk factors that could potentially impact those with DM to develop 
CDI.  
Metformin and CDI 
 Metformin is an oral medication used for the management of type II DM. There 
was one article that discussed the relationship of metformin and CDI. Metformin works 
by decreasing hepatic glucose production, decreasing intestinal glucose absorption, and 
increasing sensitivity to insulin (Vallerand & Sanoski, 2019). One study conducted by 
Eliakim-Raz et al. (2015) focused on the recurrence of CDI and its relationship to type II 
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DM. Their findings suggest that while DM appears to be a risk factor for recurrent CDI, 
metformin seems to provide a protective factor against CDI. The exact mechanism of 
protection has yet to be fully understood.  
 There is evidence that suggests that metformin has a significant change in the 
composition of gut microbiota (Rodriquez et al., 2018). Metformin increases A. 
muciniphilia and Lactobacillus both of which have been shown to benefit the host 
(Rodriquez et al., 2018). Four studies have explored metformin’s effect on gut microbiota 
(Derrien et al., 2010; Lee & Ko, 2014; Deng at al., 2018; Zhou, 2018). Metformin 
increases the amount of bacteria called Akkermansia muciniphila within gut microbiota 
(Lee & Ko, 2014). A. muciniphila is inversely related to obesity, DM, inflammation, and 
metabolic disorders (Zhou, 2018). A. muciniphila colonizes the gut mucosa and 
modulates basal metabolism. A. muciniphila is a mucin-degrading bacterium, meaning 
that they have an increased ability to survive in more extreme GI conditions such as lack 
of food or severe diarrhea than food-dependent bacteria (Derrien et al., 2010).  
Deng et al. (2018) found that A. muciniphilia had a protective factor against CDI. 
B. fragilis, another bacterium, was given to mice with CDI in order to help rebuild gut 
microbiota. When B. fragilis was given, A. municiphilia levels increased. It was found 
that B. fragilis was an effective prophylactic treatment in helping to reduce mortality 
within CDI infected mice. This was likely due to B. fragilis and A. muciniphilia’s ability 
to reduce C. difficile colonization and modulate gut microbiota. They also helped relieve 
stress on the epithelium and pathogenic colitis, by reducing mucosal barrier destruction 
(Deng et al., 2018).  
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Conclusion 
CDI is a potentially life threatening and costly HAI (healthcare-acquired 
infection). The link between DM and CDI is not well understood and needs to be further 
explored. Based on the health conditions and immune dysfunction that is caused by DM, 
there is reason to believe that those with DM may be more likely to develop CDI. This 
study contributes to the science linking risk factors and CDI, which can guide processes 
and procedures to improve patient safety within healthcare facilities. 
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CHAPTER II: METHODS 
Study Design 
 A pilot study using a quantitative, case/control design was conducted to determine 
if there was a link between DM and CDI within an acute care setting. This study was 
used to evaluate if those that had CDI were more likely to have DM than those that do not 
have CDI. This information adds to the science about CDI and risk factors that could 
provide information to improve patient safety (with a full study). This pilot study will 
also help determine the feasibility of a larger study. 
Internal Review Board #20-1-N-004 
The Internal Review Board (IRB) at the University of Maine and a medical center 
in Maine approved this study (See Appendix A for IRB Form and Application). This 
study met the criteria for an exemption determination under category 4(iii): secondary 
research for which informed consent is not required. In addition, the University of Maine 
required an application to be submitted/approved during the COVID-19 pandemic for 
research essentiality and to ensure that safety measures were considered during the data 
collection/analysis process (See Appendix B for approval notice). The use of the 
following protected health information was determined necessary for this project: Name, 
MRN, DOB, patient-specific dates, and medical information from medical and laboratory 
records including date of admission (2016-2018), diagnosis and comorbidity (DM type I 
or II Y/N) and lab results (CDI Y/N).  
The research involves only information collection and analysis involving the 
investigator’s use of identifiable health information when that use is regulated under 45 
CFR parts 160 and 164, subparts A and E, for the purposes of ‘research’ as defined at 45 
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CFR 164.501. The selected medical center’s IRB/Privacy Board approved the waiver of 
HIPAA authorization via the expedited process for the research which involves a chart 
review. This was based on the following criteria: (1) the use or disclosure of protected 
health information involves no more than a minimal risk to the privacy of individuals, 
based on the presence of the following elements: an adequate plan to protect the 
identifiers from improper use and disclosure; an adequate plan to destroy the identifiers at 
the earliest opportunity consistent with conduct of the research, unless there is a health or 
research justification for retaining the identifiers or such retention is otherwise required 
by law; and adequate written assurances that the protected health information will not be 
reused or disclosed to any other person or entity, except as required by law, for 
authorized oversight of the research study, or for other research for which the use or 
disclosure of protected health information would be permitted by this subpart; (2) the 
research could not practicably be conducted without the waiver or alteration; and (3) the 
research could not be practicably be conducted without access to and use to the protected 
health information.  
Study Preparation and Data Collection Process 
Data collection consisted of a few steps. The first step included requesting two 
lists of patients that would later be identified as either cases or controls, from the medical 
records (MR) department guided by exclusion and inclusion criteria from the research 
team. The first list included medical charts that met inclusion criteria of those with 
positive C. difficile culture and with admission dates between December, 2016 to 
December, 2018. Both case and control lists utilized exclusion criteria for oncological 
patients and patients under 18 years of age. The purpose in excluding oncology patients 
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was due to the potentially negative effect chemotherapy and other cancer medications 
have on the immune system. 
The second list received included patients with no positive C. difficile culture and 
with admission dates between December 2016 to December 2018. Both lists provided 
medical record numbers (MRNs). Second, the lists needed to be protected from 
accessibility by anyone outside of this study because patient identifiable data (MRNs) 
was provided by the MR department. The files were sent securely to Dr. Saber’s Northern 
Light work email and stored in a W drive on Dr. Saber’s password protected computer 
(See Appendix C for Letter Request). Files that were received via emails with identifiable 
information were destroyed within 48 hours of receipt after the files were secured in the 
W drive. A W drive is a work drive that can only be utilized by employees. This drive 
was available for use due to Dr. Saber’s employment status by the selected medical 
center. All files within the W drive pertaining to this research study will be destroyed by 
September 1, 2020.  
An excel software program was used to create a list of the selected cases and 
controls for the study analysis. Each excel file (within the W drive), was provided an 
extra layer of protection through password protection. One list was labeled Cdiff_Linking 
List’ (cases) and the other list was labeled Noncdiff_Linking List (controls). The search 
criteria yielded a total of 1,679 patient medical charts meeting eligibility criteria, of 
which 186 were classified as cases and 1307 as controls. At random, 40 cases (labeled 1-
40) and 40 controls (labeled 41-80) were selected from the lists (see Table 1 for example 
of linking list). This was done by selecting every 4th MRN from the ‘CDI’ list and every 
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4th MRN from the ‘No CDI list’. Participant’s MRNs were not provided by the MR 
department in any particular order (e.g., not alphabetized), to limit selection bias. 
 
Table 1. Shows Organization Method of Participant Data on each Linking List. 
Participant MRN 
1 XXXXXXXX 
2 XXXXXXXX 
3 XXXXXXXX 
4 XXXXXXXX 
5 XXXXXXXX 
6 XXXXXXXX 
 
Using the de-identified linking list, MRNs were utilized to search for the correct 
participant. Charts were analyzed for the presence of DM as a comorbidity. DM was 
labeled under many search terms: Type I DM, Type I diabetes, Type II DM, Type II 
diabetes, insulin-dependent diabetes, diabetes, and diabetes mellitus. Two columns were 
added to the linking lists to accommodate the presence or absence of CDI and DM, as 
depicted in Tables 2 and 3. A ‘yes’ indicated a positive presence and ‘no’ indicated an 
absence. 
 
Table 2. Shows How Data was Organized on ‘CDI_linking_list’ 
 
Participant  MRN CDI DM 
1 XXXXXXX Yes Yes 
2 XXXXXXX Yes No 
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Table 3. Shows How Data was Organized on ‘No_CDI_linking_list’ 
 
Participant MRN CDI DM 
1 XXXXXXX No Yes 
2 XXXXXXX No No 
 
Each ‘yes’ answer was converted to a numerical value of 1 and each ‘no’ answer was 
converted to a numerical value of 0.  
Analysis 
SPSS version 25 was used to analyze for the difference between groups, a chi-
square 2 x 2 goodness of fit test was used. The p level was set at <0.05. A chi-square test 
is a non-parametric statistical analysis that calculates for the difference between groups 
when the variables are measured at a nominal level. Chi square 2x2 is testing whether the 
observed frequencies are statistically significant from the expected frequencies. The 
expected frequency (null hypothesis) is that those that had CDI are not more likely to 
have DM than those that do not have CDI. The observed frequency (alternative 
hypothesis) is that those that had CDI are more likely to have DM that those that do not 
have CDI.  
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CHAPTER III: RESULTS 
Results 
Overall, 80 charts were reviewed (N=80). Of those, 40 participants (50%) had 
known positive culture of C. difficile (n=40) and 40 participants (50%) had no positive 
culture of C. difficile (n=40). Twenty-nine participants (26.3%) had a known diagnosis of 
DM, and 51 (63.7%) participants had no diagnosis of DM. Twenty-four participants 
(30%) had no diagnosis of C. difficile and no diagnosis of DM; 16 participants (20%) had 
no diagnosis of C. difficile and a positive diagnosis of DM; 27 participants (33.75%) had 
a positive diagnosis of C. difficile and no diagnosis of DM; and 13 participants (16.25%) 
had a positive diagnosis of C. difficile and a positive diagnosis of DM (See Table 4 for 
Cross-tabulation).   
 
Table 4. Shows the Crosstabulation of a diagnosis of DM and a diagnosis of C.difficile 
 
After performing the chi square 2x2 test, the p value was calculated at 0.485 (See 
Table 5 for results of the Chi-Square tests). Due to the p value being greater than 0.05, 
there was no statistical significance between participants with and without a diagnosis of 
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C. difficile and DM. We cannot reject the null hypothesis. Therefore, we cannot conclude 
that there is a relationship between a diagnosis of C .difficile and a diagnosis of DM 
within this population.   
 
Table 5. Results of the Chi-Square Tests. The Value at the Intersection of 
‘Asymptomatic Significance’ and ‘Pearson Chi-Square’, 0.485,  is the p Value Generated 
through SPSS Analysis 
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CHAPTER IV: DISCUSSION, LIMITATIONS, AND CONCLUSION 
Discussion and Limitations 
There were several limitations to this study. Medical charts were reviewed at one 
hospital; therefore, only a small amount of the population was captured, narrowing the 
scope of the data collected. Data collection took place in Bangor, Maine. Bangor is home 
to 1,344,212 people. Of these, 21.2% are over the age of 65 and 94.4% are of white race 
(U.S. Census Bureau, 2019). Bangor is not an urban area, nor is it diverse in terms of 
race. For this reason, generalizing the findings of this study is not accurate, as many 
important factors like socioeconomic status, race, and age, were left out.   
Only data relating to DM and CDI diagnosis were collected, leaving out 
demographics or other underlying comorbidities. Although race and ethnicity were not 
captured for this study, the selection of charts for review could be predominantly White 
since the study was conducted in an area that is not ethnically diverse. This narrowed the 
study further, and could have influenced whether this area had a higher or lower 
incidence of CDI or DM. While ethnicity is not a reported risk factor by the CDC, it 
could play a role in the acquisition of CDI. Ethnicity would have been an important factor 
to consider, since CDI and DM rates could vary between ethnicities. Another 
demographic not collected was age. The CDC (2020a) reports increased age as a risk 
factor for CDI. Age was not included in data collection, and this would be an important 
factor to consider, especially because it is a known risk factor. In order to more 
accurately describe the relationship between DM and CDI, other risk factors, specifically 
known ones, must be noted. In future studies, it would be desirable to include important 
demographics, such as race, ethnicity, and age. 
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During data collection, anecdotally, many patients with a positive CDI culture had 
a history of cancer, a previous diagnosis of CDI or another GI disturbance (i.e., ulcerative 
colitis). This could have influenced an individual’s acquisition of CDI. It may be 
advantageous to look at other comorbidities, to explore their potential relationship with 
CDI.  
This study was completed with a time constraint. Due to the COVID-19 
pandemic, academic and graduation requirements were expedited, putting the deadline of 
this study four months earlier than expected. In addition, COVID-19 had a negative 
impact on research in general. Additional forms needed to be completed, in order to 
ensure research feasibility with current social distancing requirements as outlined by the 
CDC and the governor of Maine. Research essentiality also had to be addressed. Because 
CDI is an infectious disease, this research was deemed essential.  
Future Directions 
In this study, there was no statistically significant difference in the frequency of 
CDI between individuals with DM and the control group of individuals without DM. 
However, this study provides an opportunity for future research to consider risk factors 
that may adversely affect health outcomes of individuals with DM who acquire CDI. For 
example, do individuals with DM who have higher hemoglobin A1c levels have poorer 
health outcomes when infected with CDI than individuals with lower hemoglobin A1c 
levels? Increased understanding of risk factors that result in poorer health outcomes for 
individuals with CDI may facilitate the development of targeted prevention interventions.   
Further, this study may also generate additional research questions focused on the 
relationship between other comorbidities and an individual’s risk of both acquisition of 
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CDI and health outcomes as a result of CDI. The Elixhauser comorbidity indexes which 
use ICD 10 codes to determine the risk of comorbidities on selected diseases might be 
used to further understand the risk of specific comorbidities and CDI. This information 
can be applied to preventing, altering care, or providing closer observation to those at 
higher risk. These opportunities for further research hold promise to increase safety, save 
healthcare dollars, and improve quality of life. 
Conclusion 
The relationship between CDI and DM is still an area to be explored to better 
understand potential risk factors for CDI. Identifying potential risk factors for CDI is a 
valuable source of information because it will allow for a more tailored approach in 
developing preventable measures, which will have the potential to influence how care is 
applied especially among vulnerable populations. Currently, CDI is an urgent health care 
crisis making this a critical area of research. Although the findings from this preliminary 
pilot study were not statistically significant, this was the first step in critically analyzing 
the relationship between CDI and DM. From this, more research studies exploring the 
link between CDI and DM will be developed that will enhance the field of infectious 
disease and ultimately lead to more informed, quality patient care.  
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APPENDIX C: Letter to the Medical Records Department 
 
 
 
Good morning, 
I hope you can help me or direct me to the correct person. 
We are conducting a chart review study that is titled Clostridioides difficile Infection 
Rates and Diabetes Mellitus in the Acute Care Hospital Setting: A Pilot 
Retrospective Study, which has been approved by the NLEMMC IRB: IRB # 20-1-N-
004. I attached the approval letter from Liz Carroll. 
We are requesting records for a chart review with the following criteria:  
  
No oncology patients (Grant 6 patients) 
No patients under the age of 18 
  
1. A list of patients (with MRN) with admission dates from 12/1/2016 -12/31/2018 
with positive Clostridium difficile culture (infection) 
2. A list of patients (with MRN) with admission dates from 12/1/2016 -12/31/2018 
with no positive Clostridium difficile culture (infection) 
 The only identifiable information required for these patients is the MRN. Please send the 
lists to Debbie Saber at dsaber@emhs.org. 
  
Thank you so very much for your time. Please let me know if you have any questions. 
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